Navigation Links
Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research
Date:7/27/2009

New York, NY The Lymphoma Research Foundation (LRF) is pleased to announce that the 2009 Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation Clinical Investigator Career Development Award has been awarded to Kai Fu, MD, PhD, Associate Professor at the Nebraska Medical Center in Omaha, Nebraska.

Lymphoma, the most common type of blood cancer, is broadly categorized into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). According to a 2008 report from the World Health Organization, there are six types of HL and over 61 types of NHL; many of which are rare diseases.

A member of LRF's Mantle Cell Lymphoma Consortium (MCLC), Dr. Fu's work will focus on mantle cell lymphoma (MCL), an aggressive malignant B-cell form of non-Hodgkin lymphoma (NHL). Mantle cell lymphoma is a rare form of NHL accounting for 6 percent of all new diagnoses of NHL or approximately 3,000 new cases per year in the United States. Mantle cell usually affects men over 60 and is frequently diagnosed as a Stage IV disease, often present in lymph nodes above and below the diaphragm and in most cases involves the gastrointestinal tract and bone marrow.

MCL is characterized by over expression of the gene cyclin D1 due to a chromosomal translocation. A subset of MCL also expresses higher levels of a group of small RNA molecules, called miR-17~92. Dr. Fu and his co-workers have found that higher expression of miR-17~92 is directly correlated with poorer patient survival. These findings indicate that higher miR-17~92 expression induces abnormal activation of a pathway in tumor cells that leads to increased resistance to standard chemotherapy. Dr. Fu will conduct a pre-clinical study to determine whether suppression of miR-17~92 will improve the effect of chemotherapy. His study will thus provide a novel approach to treating MCL patients.

"Dr. Fu's elegant proposal explores a new avenue for understanding MCL and identifying potential therapeutic targets. We are delighted that Dr. Fu has chosen MCL as the focus of his Clinical Career Development Project," stated Michael Williams, MD, Director, Hematologic Malignancy Program - University of Virginia and Chair of LRF's Mantle Cell Consortium

The 3-year Clinical Investigator Career Development Award is designed to fund training of clinicians who will participate in developing new therapeutics and diagnostic tools for lymphoma.

The focus of the training is to prepare clinicians to design and administer clinical studies in lymphoma and to take on the primary responsibilities for clinical trial design, protocol writing, Institutional Review Board (IRB) submission, and publication. Dr. Fu will be pursuing a Career Development Plan with the guidance of his mentor, Dr. Wing Chan, Co-Director, Center for Lymphoma and Leukemia Research, at the University of Nebraska Medical Center, Omaha, NE. Dr. Fu will be supported by a grant of $300K over 3 years to accomplish his research project. The LRF thanks Millennium Pharmaceuticals, Inc./The Takeda Oncology Company for their generous support of this grant.

"We are proud to be able to support lymphoma research through grants such as this one, and we are hopeful that the work we support may someday be a significant contribution to the discovery of new methods for treating blood cancer," said Dixie-Lee Esseltine, M.D., Vice President, Global Medical Affairs, Millennium.


'/>"/>

Contact: Marion F. Swan
mswan@lymphoma.org
212-349-6435
Lymphoma Research Foundation
Source:Eurekalert

Related medicine news :

1. Advocates for Health Millennium Development Goals Unite to Demand World Leaders Honor Funding Commitments
2. Armed Forces Retirement Home Selects Millenniums Pharmacy Services
3. Pharmacomechanical Thrombectomy Procedure Adoption to Accelerate Due to More Aggressive Treatment of Deep Vein Thrombosis, According to Millennium Research Group
4. Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
5. Industry Veteran Stephen Duvall Joins Millennium Management Team
6. Screening Programs to Drive European GI Videoscope Market Despite Economic Downturn, According to Millennium Research Group
7. Millennium Research Groups New Perception Pulse Product Offers Clients an Innovative New Customer Behavior and Loyalty Tracking Tool
8. Although the Health Care Market is Recession-Resistant, It Is Not Recession-Immune, According to Millennium Research Groups Medtech Economic Quarterly Publication
9. US Spinal Nonfusion Procedures Set to Increase Nearly Five Times From 2008 to 2013, According to Millennium Research Group
10. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
11. Thrombectomy Device Market to Approach $300 Million by 2013, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 2017 , ... MLM Insurance Group, a Miami area provider ... is working to support the Take Stock In Children Foundation during a regional ... The Take Stock In Children Foundation (TSC) offers guidance and assistance to low ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... of highly trained practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, ... hormone imbalance and conditions of aging, such as menopause, andropause, thyroid disorder and ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: ... of a couple that grew stronger together through the faith they shared to overcome ... Trials” is the creation of published author, Barbara J. Corcoran, a retired teacher and ...
(Date:8/18/2017)... ... August 18, 2017 , ... Rollon Skin Care Ltd., ... solutions, recently announced the launch of two new skincare products, Prache Antiaging ... alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “We are ...
(Date:8/17/2017)... ... 17, 2017 , ... Riccobene Associates Family Dentistry, the Research ... to its family of practices. Residents of Goldsboro will be able to experience ... , Riccobene Associates Family Dentistry, founded by Dr. Michael Riccobene in 2000, ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... International plc (NASDAQ: ENDP ) today announced that ... U.S. mesh product liability claims and that it is ... claims at reasonable values. Under the agreements, Endo will ... 2017 and continuing through the fourth quarter of 2019. ... Company intends to increase its mesh product liability accrual ...
(Date:8/2/2017)... 2, 2017 Fenita J. Caldwell ... a Pinnacle Lifetime Professional in the Field of ... at Turing Pharmaceuticals, AG. Her skills and areas ... building.                ... years of experience as a highly successful sales ...
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
Breaking Medicine Technology: